Amgen, Inc. (AMGN) Shares Bought by Trust Co. of Vermont

Trust Co. of Vermont lifted its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 0.2% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 40,297 shares of the medical research company’s stock after purchasing an additional 99 shares during the period. Trust Co. of Vermont’s holdings in Amgen were worth $7,845,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Arlington Partners LLC boosted its holdings in Amgen by 86.7% in the fourth quarter. Arlington Partners LLC now owns 140 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 65 shares during the last quarter. Massey Quick Simon & CO. LLC boosted its holdings in Amgen by 710.5% in the fourth quarter. Massey Quick Simon & CO. LLC now owns 154 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 135 shares during the last quarter. Contravisory Investment Management Inc. bought a new position in Amgen in the fourth quarter valued at about $50,000. Lavaca Capital LLC bought a new position in Amgen in the fourth quarter valued at about $78,000. Finally, Moody National Bank Trust Division bought a new position in Amgen in the fourth quarter valued at about $81,000. Institutional investors own 81.79% of the company’s stock.

AMGN has been the topic of several recent research reports. Mizuho reiterated a “buy” rating and issued a $206.00 price target on shares of Amgen in a report on Friday, October 26th. Citigroup increased their target price on Amgen from $204.00 to $210.00 and gave the company a “neutral” rating in a research note on Friday, January 4th. Royal Bank of Canada reissued a “neutral” rating and issued a target price on shares of Amgen in a research note on Monday, January 14th. Goldman Sachs Group reissued a “buy” rating and issued a $232.00 target price on shares of Amgen in a research note on Thursday, January 17th. Finally, Morgan Stanley cut their target price on Amgen from $213.00 to $212.00 and set an “overweight” rating on the stock in a research note on Wednesday, December 19th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $205.77.

NASDAQ AMGN opened at $188.34 on Friday. The stock has a market cap of $120.01 billion, a PE ratio of 13.08, a price-to-earnings-growth ratio of 2.09 and a beta of 1.21. The company has a current ratio of 2.79, a quick ratio of 2.57 and a debt-to-equity ratio of 2.36. Amgen, Inc. has a one year low of $163.31 and a one year high of $210.19.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, January 29th. The medical research company reported $3.42 EPS for the quarter, topping the Zacks’ consensus estimate of $3.26 by $0.16. The company had revenue of $6.23 billion for the quarter, compared to analyst estimates of $5.88 billion. Amgen had a return on equity of 66.74% and a net margin of 35.35%. During the same quarter last year, the firm posted $2.89 earnings per share. Research analysts anticipate that Amgen, Inc. will post 13.93 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 8th. Stockholders of record on Friday, February 15th will be given a dividend of $1.45 per share. The ex-dividend date of this dividend is Thursday, February 14th. This represents a $5.80 dividend on an annualized basis and a dividend yield of 3.08%. This is a positive change from Amgen’s previous quarterly dividend of $1.32. Amgen’s dividend payout ratio (DPR) is currently 36.67%.

In other news, Director Ronald D. Sugar sold 2,000 shares of the firm’s stock in a transaction dated Thursday, February 7th. The stock was sold at an average price of $190.00, for a total transaction of $380,000.00. Following the sale, the director now owns 14,988 shares of the company’s stock, valued at $2,847,720. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website . Also, Director Tyler Jacks sold 20,000 shares of the firm’s stock in a transaction dated Thursday, December 6th. The stock was sold at an average price of $195.41, for a total value of $3,908,200.00. Following the sale, the director now directly owns 28,979 shares in the company, valued at approximately $5,662,786.39. The disclosure for this sale can be found here . In the last ninety days, insiders have sold 23,777 shares of company stock worth $4,648,718. 0.27% of the stock is currently owned by insiders.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company’s products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

Featured Article: Average Daily Trade Volume Explained

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN). Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN) Receive News & Ratings for Amgen Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Amgen and related companies with MarketBeat.com’s FREE daily email newsletter .

Click Here to Continue...


Add a Comment

Your email address will not be published. Required fields are marked *